The global childhood absence epilepsy treatment market, By Drug (Lamotrigine, Valproate, Ethosuximide, and Cannabidiol Oral Solution and CX-8998 (Phase 2 Drugs)), By Disease Type (Atypical Absence Seizures and Typical Absence Seizures), and By Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa), had a market valuation of around US$ 158.2 million in 2017, and is anticipated to grow at a CAGR of 5.4 percent during the forecast period (2018 – 2026).
Get Sample Report with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/2329
Drivers
The global childhood absence epilepsy treatment market is forecast to develop due to improved government regulations supporting the use of current medications, the availability of new medications in the pipeline, and the lack of viable therapies for children absence epilepsy. As per multiple research published by the National Center for Biotechnology Information, as well as a new suggestion by the National Institute for Health and Care Excellence (NICE), Ethosuximide should be examined first, trailed by Valproate and Lamotrigine.
Moreover, a number of companies, including Insys Therapeutics and Cavion, Inc. (CX-8998), have medications in phase II clinical trials that are projected to be released within the projected period. The advent of generic versions of medications is expected to improve therapeutic accessibility and affordability. Ethosuximide is a drug that is administered orally, and there are generic versions on the market. Ethosuximide is also available from other companies such as Akorn, Inc., Bionpharma, Inc., and Teva Pharmaceuticals USA in pill and syrup form. During the forecast period, these factors are projected to propel the global childhood absence epilepsy treatment market forward.
Browse 26 Market Data Tables and 37 Figures spread through 144 Pages and in-depth TOC on Global Childhood Absence Epilepsy Treatment Market, By Drug (Lamotrigine, Valproate, Ethosuximide, and Cannabidiol Oral Solution and CX-8998 (Phase 2 Drugs)), By Disease Type (Atypical Absence Seizures and Typical Absence Seizures), and By Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) – Global Forecast to 2026
Market players are introducing generic versions of pharmaceuticals in both established and emerging markets. In 2015, Greenstone, LLC, a generic pharmaceutical firm and a fully owned subsidiary of Pfizer Inc., introduced Zarontin capsules and oral solution as an approved generic (Pfizer’s own generic version). In the year 2000, Dr. Reddy’s Laboratories introduced generic lamotrigine orally disintegrating pills to the market. Handa Pharmaceuticals, Inc. also stated that in 2017, TruPharma, LLC began marketing and distributing Handa’s FDA-approved Abbreviated New Drug Application for Lamotrigine Extended Release Tablets in the U.S. In 2014 and 2013, Mylan Laboratories and Wockhardt, respectively, released generic versions of Lamictal.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/2329
Key Takeaways
Due to increased research and development initiatives by major players in the children absence epilepsy treatment business, the global childhood absence epilepsy treatment market is estimated to grow at a CAGR of 4 percent during the forecast period.
Since pipeline medications are currently in the second round of clinical testing, they are likely to hit the market in 2021.
Due to new product introductions, the global childhood absence epilepsy treatment market in North America is projected to develop at the fastest rate during the forecast period.
Though the incidence of epilepsy is greater in developing economies such as Asia Pacific and Africa than in established nations, these nations have a poor diagnostic percentage and treatment accessibility. As per the World Health Organization, over 3/4th (75 percent) of epilepsy patients residing in low and middle-income nations do not have access to care as of 2018.
Competitive Landscape
Key companies contributing in the global childhood absence epilepsy treatment market are Insys Therapeutics, Inc., Pfizer, Inc., Cavion, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, and AbbVie, Inc.
Reasons to Purchase this Report
• Current and future of global Childhood Absence Epilepsy Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Contents
- Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Disease Type
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- About Childhood Absence Epilepsy
- Diagnosis of Childhood Absence Epilepsy
- Treatment Approaches
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Regulatory Scenario
- Pipeline Analysis
- Global Childhood Absence Epilepsy Treatment Market, By Drug, 2018–2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, 2018–2026
- Segment Trends
- Ethosuximide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Valproate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Lamotrigine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Phase 2 Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Cannabidiol Oral Solution
- CX-8998
- Introduction
- Global Childhood Absence Epilepsy Treatment Market, By Disease Type, 2018–2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, 2018–2026
- Segment Trends
- Typical Absence Seizures
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Atypical Absence Seizures
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Introduction
- Global Childhood Absence Epilepsy Treatment Market, By Region, 2018–2026 (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, For Regions, 2018–2026
- North America
- Market Size and Forecast, By Drug, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Disease Type, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Disease Type, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Disease Type, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of APAC
- Latin America
- Market Size and Forecast, By Drug, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Disease Type, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Disease Type, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
- Central Africa
- South Africa
- North Africa
- Middle East
- Market Size and Forecast, By Drug, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Disease Type, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Cavion, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Insys Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cavion, Inc.
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
